13 research outputs found
MAP Kinase-Interacting Kinases—Emerging Targets against Cancer
Mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) regulate the initiation of translation through phosphorylation of eukaryotic initiation factor 4E (eIF4E). Mnk-mediated eIF4E activation promotes cancer development and progression. While the phosphorylation of eIF4E is necessary for oncogenic transformation, the kinase activity of Mnks seems dispensable for normal development. For this reason, pharmacological inhibition of Mnks could represent an ideal mechanism-based and nontoxic therapeutic strategy for cancer treatment. In this review, we discuss the current understanding of Mnk biological roles, structures, and functions, as well as clinical implications. Importantly, we propose different strategies for identification of highly selective small molecule inhibitors of Mnks, including exploring a structural feature of their kinase domain, DFD motif, which is unique within the human kinome. We also argue that a combined targeting of Mnks and other pathways should be considered given the complexity of cancer
Targeting CDK 9 for treatment of colorectal cancer
Colorectal cancer (CRC) remains one of the most lethal human malignancies and pursuit of new therapeutic targets for treatment has been a major research focus. Cyclin‐dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment. CDKI‐73, one of the most potent and pharmacologically superior CDK9 inhibitors, has demonstrated excellent anti‐tumor efficacy against several types of cancers. In this study, we evaluated its therapeutic potential against CRC. CDKI‐73 elicited high cytotoxicity against all colon cancer cell lines tested. Cell cycle and apoptosis analysis in HCT 116 and HT29 cells revealed that CDKI‐73 induced cell death without accumulation of DNA at any phase of the cell cycle. Moreover, it caused depolarisation of mitochondrial membrane leading to caspase‐independent apoptosis. Knockdown by shRNA demonstrated the CDK9 targeted mechanism of CDKI‐73, which also affected the Mnk/eIF4E signalling axis. In addition, RT‐qPCR analysis showed that CDKI‐73 downregulated multiple pro‐survival factors at the mRNA level. Its in vivo anti‐tumor efficacy was further evaluated in Balb/c nude mice bearing HCT 116 xenograft tumors. CDKI‐73 significantly inhibited tumor growth (***p < 0.001) without overt toxicity. Analysis of the tumor tissues collected from the xenografted animals confirmed that the in vivo anti‐tumor efficacy was associated with CDK9 targeting of CDKI‐73. Overall, this study provides compelling evidence that CDKI‐73 is a promising drug candidate for treating colorectal cancer
Insights into the importance of DFD-motif and insertion I1 in stabilizing the DFD-out conformation of Mnk2 kinase
Human mitogen-activated protein kinases (MAPK)-interacting kinases 1 and 2 (Mnk1/2) are promising anticancer targets. Mnks possess special insertions and a DFDmotif that are distinct from other kinases. Crystallographic studies of Mnk1/2 have revealed that the DFD-motif adopts the DFG/D-out conformation in which residue F227 flips into the ATP binding pocket. This is rarely observed in other kinases. Although the DFG-out conformation has attracted great interest for designing selective inhibitors, structural requirements for binding and the mechanism governing the DFG-out conformation remain unclear. This work presents for the first time the applicability of 3D models of Mnk2 protein in studying conformational changes by utilizing homology modeling and molecular dynamics simulations. The study reveals that the interactions between residue K234 of insertion I1 and D226 of the DFD motif play a key role in inducing and stabilizing the DFD-out conformation. The structural features will aid in the rational design of Mnk2 inhibitors.
Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery
Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase
Human
mitogen-activated protein kinases (MAPK)-interacting kinases
1 and 2 (Mnk1/2) are promising anticancer targets. Mnks possess special
insertions and a DFD-motif that are distinct from other kinases. Crystallographic
studies of Mnk1/2 have revealed that the DFD-motif adopts the DFG/D-out
conformation in which residue F227 flips into the ATP binding pocket.
This is rarely observed in other kinases. Although the DFG-out conformation
has attracted great interest for designing selective inhibitors, structural
requirements for binding and the mechanism governing the DFG-out conformation
remain unclear. This work presents for the first time the applicability
of 3D models of Mnk2 protein in studying conformational changes by
utilizing homology modeling and molecular dynamics simulations. The
study reveals that the interactions between residue K234 of insertion
I1 and D226 of the DFD motif play a key role in inducing and stabilizing
the DFD-out conformation. The structural features will aid in the
rational design of Mnk2 inhibitors
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells
The global burden of cancer necessitates rapid and ongoing development of effective cancer therapies. One promising approach in this context is the repurposing of existing non-cancer drugs for cancer indications. A key to this approach is selecting the cellular targets against which to identify novel repurposed drugs for pre-clinical analysis. Protein kinases are highly sought-after anticancer drug targets since dysregulation of kinases is the hallmark of cancer. To identify potential kinase-targeted drug candidates from the existing portfolio of non-cancer therapeutics, we used combined in silico and in vitro approaches, including ligand-based 3D screening followed by biochemical and cellular assessments. This strategy revealed that the anti-viral drug rilpivirine is an Aurora A kinase inhibitor. In view of previous findings implicating Aurora A kinase in abnormal cell cycle regulation, we also examined the influence of rilpivirine on the growth of T47D breast cancer cells. Herein, we detail the identification of rilpivirine as an Aurora A kinase inhibitor, its molecular basis of inhibitory activity towards this kinase, and its Aurora A-mediated anticancer mechanisms in T47D cells. Our results illustrate the value of integrated in silico and in vitro screening strategies in identifying repurposed drug candidates and provide a scientific basis for further exploring the potential anticancer properties of the anti-viral drug rilpivirine
Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase
Human
mitogen-activated protein kinases (MAPK)-interacting kinases
1 and 2 (Mnk1/2) are promising anticancer targets. Mnks possess special
insertions and a DFD-motif that are distinct from other kinases. Crystallographic
studies of Mnk1/2 have revealed that the DFD-motif adopts the DFG/D-out
conformation in which residue F227 flips into the ATP binding pocket.
This is rarely observed in other kinases. Although the DFG-out conformation
has attracted great interest for designing selective inhibitors, structural
requirements for binding and the mechanism governing the DFG-out conformation
remain unclear. This work presents for the first time the applicability
of 3D models of Mnk2 protein in studying conformational changes by
utilizing homology modeling and molecular dynamics simulations. The
study reveals that the interactions between residue K234 of insertion
I1 and D226 of the DFD motif play a key role in inducing and stabilizing
the DFD-out conformation. The structural features will aid in the
rational design of Mnk2 inhibitors
Discovery of <i>N</i>,4-Di(1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation
Cyclin-dependent kinase 2 (CDK2) has been garnering considerable interest as a target to develop new cancer treatments and to ameliorate resistance to CDK4/6 inhibitors. However, a selective CDK2 inhibitor has yet to be clinically approved. With the desire to discover novel, potent, and selective CDK2 inhibitors, the phenylsulfonamide moiety of our previous lead compound 1 was bioisosterically replaced with pyrazole derivatives, affording a novel series of N,4-di(1H-pyrazol-4-yl)pyrimidin-2-amines that exhibited potent CDK2 inhibitory activity. Among them, 15 was the most potent CDK2 inhibitor (Ki = 0.005 µM) with a degree of selectivity over other CDKs tested. Meanwhile, this compound displayed sub-micromolar antiproliferative activity against a panel of 13 cancer cell lines (GI50 = 0.127–0.560 μM). Mechanistic studies in ovarian cancer cells revealed that 15 reduced the phosphorylation of retinoblastoma at Thr821, arrested cells at the S and G2/M phases, and induced apoptosis. These results accentuate the potential of the N,4-di(1H-pyrazol-4-yl)pyrimidin-2-amine scaffold to be developed into potent and selective CDK2 inhibitors for the treatment of cancer
In Search of Novel CDK8 Inhibitors by Virtual Screening
Aberrant
activity of cyclin-dependent kinase (CDK) 8 is implicated
in various cancers. While CDK8-targeting anticancer drugs are highly
sought-after, no CDK8 inhibitor has yet reached clinical trials. Herein
a large library of drug-like molecules was computationally screened
using two complementary cascades to identify potential CDK8 inhibitors.
Thirty-three hits were identified to inhibit CDK8 and seven of them
were active against colorectal cancer cell lines. Finally, the primary
target was confirmed using three promising hits